Both products are aids for diagnosing disease. Resapp will initially be approved to diagnose pneumonia and asthma. The other product will be used as a step in diagnosing many more diseases, including pneumonia and asthma. Therefore, it is a competitor. And what's more, a telehealth provider is actually partnering with that company. Not saying one product is better than the other. But we can't just dismiss it.
It's best to be open-minded about competition and to look at things from the telehealth providers' perspective, not from our perspective as shareholders of RAP. Telehealth providers want to keep both patients and doctors happy, and they will navigate the territory in their own best interests.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
